CU23452B7 - Derivados de tetrahidroquinolina 4-cicloalquilo sustituidos - Google Patents

Derivados de tetrahidroquinolina 4-cicloalquilo sustituidos

Info

Publication number
CU23452B7
CU23452B7 CU20070140A CU20070140A CU23452B7 CU 23452 B7 CU23452 B7 CU 23452B7 CU 20070140 A CU20070140 A CU 20070140A CU 20070140 A CU20070140 A CU 20070140A CU 23452 B7 CU23452 B7 CU 23452B7
Authority
CU
Cuba
Prior art keywords
cicloalquilo
substituted
tetrahydroquinoline derivatives
prevention
preparation
Prior art date
Application number
CU20070140A
Other languages
English (en)
Spanish (es)
Inventor
Alexandros Vakolopoulos
Michael Thutewohl
Heike Gielen-Haertwig
Volkhart Li
Martina Wuttke
Olaf Weber
Carsten Schmeck
Hilmar Bischoff
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102004060997A external-priority patent/DE102004060997A1/de
Priority claimed from DE102004061000A external-priority patent/DE102004061000A1/de
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of CU23452B7 publication Critical patent/CU23452B7/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CU20070140A 2004-12-18 2007-06-18 Derivados de tetrahidroquinolina 4-cicloalquilo sustituidos CU23452B7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004060997A DE102004060997A1 (de) 2004-12-18 2004-12-18 Chemische Verbindung und ihre Verwendung
DE102004061000A DE102004061000A1 (de) 2004-12-18 2004-12-18 Chemische Verbindung und ihre Verwendung

Publications (1)

Publication Number Publication Date
CU23452B7 true CU23452B7 (es) 2009-12-01

Family

ID=35841894

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20070140A CU23452B7 (es) 2004-12-18 2007-06-18 Derivados de tetrahidroquinolina 4-cicloalquilo sustituidos

Country Status (27)

Country Link
US (2) US8124775B2 (enExample)
EP (1) EP1828137B1 (enExample)
JP (1) JP5132317B2 (enExample)
KR (1) KR20070090248A (enExample)
AR (1) AR055011A1 (enExample)
AT (1) ATE555097T1 (enExample)
AU (1) AU2005315770B2 (enExample)
BR (1) BRPI0519602A2 (enExample)
CA (1) CA2591397A1 (enExample)
CU (1) CU23452B7 (enExample)
CY (1) CY1112887T1 (enExample)
DK (1) DK1828137T3 (enExample)
DO (1) DOP2005000259A (enExample)
ES (1) ES2384980T3 (enExample)
GT (1) GT200500377A (enExample)
IL (1) IL184008A (enExample)
MA (1) MA29100B1 (enExample)
MX (1) MX2007007188A (enExample)
NO (1) NO20073146L (enExample)
PE (1) PE20060767A1 (enExample)
PL (1) PL1828137T3 (enExample)
PT (1) PT1828137E (enExample)
RU (1) RU2393151C2 (enExample)
SI (1) SI1828137T1 (enExample)
TW (1) TW200635900A (enExample)
UY (1) UY29276A1 (enExample)
WO (1) WO2006063828A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005324127A1 (en) * 2004-12-18 2006-07-13 Bayer Healthcare Ag (5S) -3-[(S)-fluoro (4-trifluoromethylphenyl) methyl]-5,6,7,8-tetrahydroquinoline-5-ol derivatives and use thereof as CETP inhibitors
DE102006012548A1 (de) * 2006-03-18 2007-09-20 Bayer Healthcare Ag Substituierte Chromanol-Derivate und ihre Verwendung
ATE520696T1 (de) * 2008-03-05 2011-09-15 Boehringer Ingelheim Int Tricyclische pyridinderivate, solche verbindungen enthaltende medikamente, ihre verwendung und verfahren zu ihrer herstellung
MA34007B1 (fr) 2010-02-19 2013-02-01 Boehringer Ingelheim Int Derives de pyridine tricycliques medicaments contenant ces composes leur utilisation et leur procede de preparation
US9187450B2 (en) * 2010-07-09 2015-11-17 Daiichi Sankyo Company, Limited Substituted pyridine compound
WO2012110599A1 (en) 2011-02-17 2012-08-23 Boehringer Ingelheim International Gmbh Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation
US9150583B2 (en) 2011-08-17 2015-10-06 Boehringer Ingelheim International Gmbh Furo[3,4-c]quinoline derivatives, medicaments containing such compounds, their use and process for their preparation
US9321747B2 (en) 2012-01-06 2016-04-26 Daiichi Sankyo Company, Limited Acid addition salt of substituted pyridine compound
WO2016016157A1 (en) 2014-07-30 2016-02-04 F. Hoffmann-La Roche Ag Genetic markers for predicting responsiveness to therapy with hdl-raising or hdl mimicking agent

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4128681A1 (de) * 1991-08-29 1993-03-04 Bayer Ag Substituierte mandelsaeurederivate, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
DE19610932A1 (de) 1996-03-20 1997-09-25 Bayer Ag 2-Aryl-substituierte Pyridine
DE19627430A1 (de) 1996-07-08 1998-01-15 Bayer Ag Bicyclisch kondensierte Pyridine
US6207671B1 (en) 1996-07-08 2001-03-27 Bayer Aktiengesellschaft Cycloalkano-pyridines
HRP970330B1 (en) * 1996-07-08 2004-06-30 Bayer Ag Cycloalkano pyridines
DE19627431A1 (de) 1996-07-08 1998-01-15 Bayer Ag Heterocyclisch kondensierte Pyridine
DE19704244A1 (de) 1997-02-05 1998-08-06 Bayer Ag 5-Hydroxy-alkyl substituierte Phenyle
DE19709125A1 (de) 1997-03-06 1998-09-10 Bayer Ag Substituierte Chinoline
MA24643A1 (fr) * 1997-09-18 1999-04-01 Bayer Ag Tetrahydro-naphtalenes substitues et composes analogues
DE19741051A1 (de) 1997-09-18 1999-03-25 Bayer Ag Hetero-Tetrahydrochinoline
DE19741399A1 (de) * 1997-09-19 1999-03-25 Bayer Ag Tetrahydrochinoline
DE19935966A1 (de) 1999-07-30 2001-02-01 Bayer Ag Verfahren zur Reduktion von Ketoalkoholen
DE10148436A1 (de) 2001-10-01 2003-04-17 Bayer Ag Tetrahydrochinoline
DE10250687A1 (de) 2002-10-31 2004-05-13 Bayer Ag 7H-Dibenzo(b,g)(1,5)dioxocin-5-on-Derivate und ihre Verwendung
AU2005324127A1 (en) * 2004-12-18 2006-07-13 Bayer Healthcare Ag (5S) -3-[(S)-fluoro (4-trifluoromethylphenyl) methyl]-5,6,7,8-tetrahydroquinoline-5-ol derivatives and use thereof as CETP inhibitors

Also Published As

Publication number Publication date
PE20060767A1 (es) 2006-09-10
IL184008A0 (en) 2007-10-31
US20080255068A1 (en) 2008-10-16
GT200500377A (es) 2006-11-09
MX2007007188A (es) 2007-08-14
AU2005315770B2 (en) 2011-12-08
DOP2005000259A (es) 2006-11-15
KR20070090248A (ko) 2007-09-05
ATE555097T1 (de) 2012-05-15
AR055011A1 (es) 2007-08-01
IL184008A (en) 2012-03-29
BRPI0519602A2 (pt) 2009-02-25
JP5132317B2 (ja) 2013-01-30
CY1112887T1 (el) 2016-04-13
TW200635900A (en) 2006-10-16
EP1828137B1 (de) 2012-04-25
PL1828137T3 (pl) 2012-09-28
EP1828137A1 (de) 2007-09-05
AU2005315770A1 (en) 2006-06-22
MA29100B1 (fr) 2007-12-03
NO20073146L (no) 2007-09-18
UY29276A1 (es) 2006-07-31
PT1828137E (pt) 2012-07-04
RU2393151C2 (ru) 2010-06-27
SI1828137T1 (sl) 2012-08-31
WO2006063828A1 (de) 2006-06-22
US8124775B2 (en) 2012-02-28
US20120142728A1 (en) 2012-06-07
CA2591397A1 (en) 2006-06-22
DK1828137T3 (da) 2012-07-23
RU2007127127A (ru) 2009-01-27
ES2384980T3 (es) 2012-07-16
JP2008524145A (ja) 2008-07-10

Similar Documents

Publication Publication Date Title
CU23452B7 (es) Derivados de tetrahidroquinolina 4-cicloalquilo sustituidos
CL2008003407A1 (es) Compuestos derivados de aril- y heteroarilcarbonilo de heterobiciclo sustituido; composicion farmaceutica; procedimiento de preparacion; y su uso en el tratamiento y/o prevencion de trastornos metabolicos, mediado por la inhibicion de la enzima hsd-1.
UY31526A1 (es) 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso
ECSP13012668A (es) Ácidos 1-bencilcicloalquilcarboxílicos sustituidos y su uso
CL2007003874A1 (es) Compuestos derivados de benzamida; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedades cardiovasculares, hipertension, aterosclerosis, reestenosis, ictus, insuficiencia cardiaca, lesion isquemica, hipertensio
BRPI0915300B8 (pt) compostos de éster boronato e composições farmacêuticas dos mesmos
EA201101190A1 (ru) Фармацевтическая композиция, включающая линаглиптин и необязательно ингибитор sglt2, и ее применение
CL2008001457A1 (es) Compuestos derivados de 6-(piridin-3-il)quinolina, inhibidores de la pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de cancer en un humano que lo necesite.
UY31765A (es) Dihidropirazolonas sustituidas y su uso
AR058098A1 (es) Derivados de acidos dicarboxilicos y su uso
PA8770101A1 (es) Amidas de 4-aril-1,4-dihidro-1, 6-naftiridina sustituidas y su uso
WO2010031184A8 (en) Azaindole derivatives as crth2 receptor antagonists
MX338088B (es) Imidazoquinolinas y derivados de pirimidina como moduladores potentes de los procesos angiogenicos impulsados por el factor de crecimiento endotelial vascular (vegf).
ECSP088745A (es) Derivados sustituidos de cromanol y su uso
WO2008076954A3 (en) Heterocycle compounds and methods of use thereof
WO2009099553A3 (en) Use of kinase inhibitor in treatment of atherosclerosis
CL2007002376A1 (es) Compuestos derivados de pirrol sustituido; proceso de preparacion; composicion farmaceutica; y uso en enfermedades bacterianas.
CU20100111A7 (es) 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso para el tratamiento y prevención de enfermedades pulmonares y cardiovasculares
WO2009071689A3 (de) 5-halogen-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
IL195473A (en) Diphosphate Acetic Acid Derivatives as Glycine Transporter Inhibitors-1, Method for Preparing, Using Pharmaceutical Preparations
CL2009000510A1 (es) Compuestos derivados de 1,3,5,6,7,8-hexahidro-furo[3,4-b]quinolina, inhibidores de cetp; proceso de preparacion de los compuestos; composicion farmaceutica; proceso de preparacion de la composicion; y uso en el tratamiento y/o prevencion de trastornos cardiovasculares y trastornos relacionados.
PA8806501A1 (es) Triazolotriazinas y triazolopirazinas y su uso
GT200600109A (es) Derivados de acido pirimidincarboxilico y su uso
CR11869A (es) 7-sulfanilmetil-, 7-sulfinilmetil- y 7-sulfonilmetilindoles sustituidos y el uso de los mismos
EP2322505A4 (en) 1-ADAMANTYLAZETIDIN-2-ON DERIVATIVE, PREPARATION THEREOF AND PHARMACEUTICAL PREPARATION THEREWITH

Legal Events

Date Code Title Description
FD Lapse (for not paying fees)